Shima M - This study was performed to examine the therapeutic efficacy of prophylactic emicizumab compared with on-demand bypassing agents (activated factor VII or activated prothrombin complex concentrate) in reducing bleeding rates among children with Hemophilia A and factor VIII (FVIII) inhibitors. Significantly fewer bleeding events were observed with emicizumab prophylaxis.